Cordy P E, Gagnon R, Taves D R, Kaye M
Can Med Assoc J. 1974 Jun 22;110(12):1349-53.
Forty-one patients on our chronic hemodialysis program were assessed for the degree of progression of bone disease over an average period of 46 months. Seven patients were using a fluoridated dialysate. Four of these seven patients developed a marked increase in osteoid as judged by bone biopsy, while in the nonfluoridated group the amount of osteoid remained within normal limits.In the absence of fluoride, although osteitis fibrosa occurred, it was reversible in 10 out of 12 cases by dihydrotachysterol treatment, and overall there was no evidence of progression of bone disease at the end of the study period.
我们对41名接受慢性血液透析治疗的患者进行了评估，观察他们在平均46个月的时间里骨病的进展程度。7名患者使用了含氟透析液。在这7名患者中，根据骨活检判断，有4名患者的类骨质显著增加，而在未使用含氟透析液的组中，类骨质数量保持在正常范围内。在没有氟的情况下，虽然发生了纤维性骨炎，但12例中有10例通过双氢速甾醇治疗可逆转，并且在研究期结束时总体上没有骨病进展的证据。
